ArticleJNCI cancer spectrum2019

Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis.

Hadar Goldvaser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.